Go to PiHKAL • info home
Browse the short index of PiHKAL phenethylamines. Read book II of PiHKAL
Search for phenethylamines and related structures Beyond PiHKAL—Selected writings by Sasha and others. Explore phenethylamine structures and analogues
The essential oils and their amphetamine analogues How PiHKAL • info differs from the printed version
Go to TiHKAL • info home
You are currently exploring MLD-41.
To explore a different substance, type its name: Help
MLD-41; N,N-Diethyl-1-methyllysergamide
5302
Variant: N R1 R2 skeleton isomers all
Analogues: 2 4 2 1 6 15

IUPAC: (8β)-N,N-Diethyl-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide

Formula: C21H27N3O Molecular weight: 337.45858 g/mol InChI Key: VQZYKSWQIQANKB-DNVCBOLYSA-N

InChI=1S/C21H27N3O/c1-5-24(6-2)21(25)15-10-17-16-8-7-9-18-20(16)14(12-22(18)3)11-19(17)23(4)13-15/h7-10,12,15,19H,5-6,11,13H2,1-4H3/t15-,19-/m1/s1

PubChem CID: 165200; ChemSpider: 144824; Wikipedia: MLD-41

See also TiHKAL: #26 LSD #48 α-MT      

Abramson, HA. Lysergic acid diethylamide (LSD-25) XXXI. Comparison by questionnaire of psychotomimetic activity of congeners on normal subjects and drug addicts. Br. J. Psychiatry, 1 Jul 1960, 106 (444), 1120–1123. 425 kB. doi:10.1192/bjp.106.444.1120

Two N analogues:
5339
Analogue 1: Substituting Ethyl for Diethyl at N

MLA-74
N-Ethyl-1-methyllysergamide

IUPAC: (8β)-N-Ethyl-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide

Formula: C19H23N3O Molecular weight: 309.40542 g/mol InChI Key: OLUVTYNEBIODME-CXAGYDPISA-N

InChI=1S/C19H23N3O/c1-4-20-19(23)13-8-15-14-6-5-7-16-18(14)12(10-21(16)2)9-17(15)22(3)11-13/h5-8,10,13,17H,4,9,11H2,1-3H3,(H,20,23)/t13-,17-/m1/s1

PubChem CID: 201993; ChemSpider: 174916

See also TiHKAL: #26 LSD        
5340
Analogue 2: Substituting 1-Hydroxybutan-2-yl for Diethyl at N

UML-491
Methysergide
Sansert
N-(1-Hydroxybutan-2-yl)-1-methyllysergamide

IUPAC: (8β)-N-(1-Hydroxybutan-2-yl)-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide

Formula: C21H27N3O2 Molecular weight: 353.45798 g/mol InChI Key: KPJZHOPZRAFDTN-NQUBZZJWSA-N

InChI=1S/C21H27N3O2/c1-4-15(12-25)22-21(26)14-8-17-16-6-5-7-18-20(16)13(10-23(18)2)9-19(17)24(3)11-14/h5-8,10,14-15,19,25H,4,9,11-12H2,1-3H3,(H,22,26)/t14-,15?,19-/m1/s1

PubChem CID: 9681; ChemSpider: 5022813; Wikipedia: Methysergide

See also TiHKAL: #6 DMT #26 LSD      
Four R1 analogues:
5026
Analogue 1: Removing Methyl at R1

LSD
LSD-25
METH-LAD
Acid
N,N-Diethyllysergamide
Lysergide
d-Lysergic acid diethylamide
d-Lysergamide, N,N-diethyl
N,N-Diethyl-d-lysergamide
9,10-Didehydro-N,N-diethyl-6-methylergoline-8β-carboxamide

IUPAC: (8β)-N,N-Diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide

Formula: C20H25N3O Molecular weight: 323.432 g/mol InChI Key: VAYOSLLFUXYJDT-RDTXWAMCSA-N

InChI=1S/C20H25N3O/c1-4-23(5-2)20(24)14-9-16-15-7-6-8-17-19(15)13(11-21-17)10-18(16)22(3)12-14/h6-9,11,14,18,21H,4-5,10,12H2,1-3H3/t14-,18-/m1/s1

PubChem CID: 5761; ChemSpider: 5558; Drugs Forum: LSD; Erowid: LSD; Wikipedia: Lysergic acid diethylamide

See also PiHKAL: #5 ALEPH-4
#6 ALEPH-6
#7 ALEPH-7
#9 ASB
#21 3C-BZ
#25 3C-E
#28 2C-G-3
#30 2C-G-5
#31 2C-G-N
#41 2C-T-4
#43 2C-T-7
#52 DESOXY
#58 DMMDA
#62 DOB
#66 DOET
#67 DOI
#68 DOM
#69 Ψ-DOM
#79 F-2
#80 F-22
#81 FLEA
#97 4-MA
#100 MDA
#101 MDAL
#108 MDIP
#111 MDMEO
#118 MDPR
#125 META-DOT
#132 MMDA
#134 MMDA-3a
#156 4-TM
#160 TMA-4
#161 TMA-5
#170 5-TOET
See also TiHKAL: #1 AL-LAD
#2 DBT
#6 DMT
#9 DPT
#12 ETH-LAD
#16 4-HO-DET
#17 4-HO-DIPT
#18 4-HO-DMT
#19 5-HO-DMT
#28 4,5-MDO-DIPT
#37 5-MeO-DIPT
#48 α-MT
#51 PRO-LAD
#53 T
#57 DALT

See also Transcripts: 2.214, 2.247, 2.249, 2.256, 2.267, 2.269, 2.288, 2.317, 2.323.2, 3.330, 3.336, 3.344, 3.366, 3.376, 3.387, 3.398, 3.399, 3.405, 4.469, 4.508, 5.600, 5.601, 5.622, 5.623, 5.624, 5.632, 5.657, 5.658, 5.659, 5.660, 5.662

See also Pharmacology notes II: app. 2, Abuse week
p. 214, LSD: A recalibration
p. 247, LSD: Window exploitation studies
p. 249, LSD: Window exploitation studies
p. 256, LSD: Window exploitation studies
p. 267, LSD: Window exploitation studies
p. 269, LSD: Calibration
p. 288, LSD: Primer studies
p. 317, LSD: Primer studies

Fenderson5555. Total synthesis of lysergic acid. 25 Jun 2011. 4413 kB.

Fenderson5555. Total synthesis of lysergic acid via Pd-catalysed domino cyclizations. 4 Dec 2011. 6394 kB.

Fenderson5555. A more modern lysergic acid synthesis. 28 Jun 2011. 3348 kB.

Schulze-Alexandru, M; Kovar, K; Vedani, A. Quasi-atomistic receptor surrogates for the 5-HT2A receptor: A 3D-QSAR study on hallucinogenic substances. Quant. Struct.-Act. Relat., 1 Dec 1999, 18 (6), 548–560. 312 kB. doi:10.1002/(SICI)1521-3838(199912)18:6<548::AID-QSAR548>3.0.CO;2-B

Ginzel, KH; Mayer-Gross, W. Prevention of psychological effects of d-lysergic acid diethylamide (LSD 25) by its 2-brom derivative (BOL 148). Nature, 28 Jul 1956, 178 (4526), 210. 129 kB. doi:10.1038/178210a0

Glennon, RA; Raghupathi, R; Bartyzel, P; Teitler, M; Leonhardt, S. Binding of phenylalkylamine derivatives at 5-HT1C and 5-HT2 serotonin receptors: evidence for a lack of selectivity. J. Med. Chem., 1 Feb 1992, 35 (4), 734–740. 1054 kB. doi:10.1021/jm00082a014

Gorodetzky, CW; Isbell, H. A comparison of 2,3-dihydro-lysergic acid diethylamide with LSD-25. Psychopharmacology, 1 May 1964, 6 (3), 229–233. 317 kB. doi:10.1007/BF00404013

Parrish, JC. Toward a molecular understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2006. 5475 kB.

McDonald, P; Martin, CF; Woods, DJ; Baker, PB; Gough, TA. An analytical study of illicit lysergide. J. Forensic Sci., 1 Jan 1984, 29 (1), 120–130. 493 kB. doi:10.1520/JFS11642J

Moreno, JL; Holloway, T; Albizu, L; Sealfon, SC; González-Maeso, J. Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists. Neurosci. Lett., 15 Apr 2011, 493 (3), 76–79. 196 kB. doi:10.1016/j.neulet.2011.01.046

Passie, T; Halpern, JH; Stichtenoth, DO; Emrich, HM; Hintzen, A. The pharmacology of lysergic acid diethylamide: A review. CNS Neurosci. Ther., 1 Jan 2008, 14 (4), 295–314. 690 kB. doi:10.1111/j.1755-5949.2008.00059.x

Green, AR. Gaddum and LSD: the birth and growth of experimental and clinical neuropharmacology research on 5-HT in the UK. Br. J. Pharmacol., 1 Aug 2008, 1554 (8), 1583–1599. 418 kB. doi:10.1038/bjp.2008.207

Chemel, BR. Exploring the molecular determinants of binding selectivity and efficacy for D1 dopamine receptor agonists. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 May 2010. 1919 kB.

Bailey, K; Verner, D; Legault, D. Distinction of some dialkyl amides of lysergic and iso-lysergic acids from LCD. J. Assoc. Anal. Chem., 1973, 56 (1), 88–99. 513 kB.

Gomes, MM; Dörr, FA; Catalani, LH; Campa, A. Oxidation of lysergic acid diethylamide (LSD) by peroxidises: a new metabolic pathway. Forensic Toxicol., 1 Jul 2012, 30 (2), 87–97. 632 kB. doi:10.1007/s11419-011-0131-4

Veress, T. Study of the extraction of LSD from illicit blotters for HPLC determination. J. Forensic Sci., 1 Sep 1993, 38 (5), 1105–1110. 348 kB. doi:10.1520/JFS13514J

Nichols, DE. LSD and its lysergamide cousins. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 80–87. 270 kB.

Martin, DA; Marona-Lewicka, D; Nichols, DE; Nichols, CD. Chronic LSD alters gene expression profiles in the mPFC relevant to schizophrenia. Neuropharmacology, 1 Aug 2014, 83, 1–8. 1213 kB. doi:10.1016/j.neuropharm.2014.03.013

Schindler, EAD. Behavioral and biochemical distinctions in the pharmacology of two common hallucinogens. Ph. D. Thesis, Drexel University, Philadelphia, PA, USA, 1 Apr 2010. 5870 kB.

Ang, RLL. Molecular basis of the action of hallucinogens. Ph. D. Thesis, New York University, New York, NY, USA, 2010. 2402 kB.

Reissig, CJ. The 5-HT1A receptor and hallucinogens. Ph. D. Thesis, State University of New York, Buffalo, NY, USA, 7 Sep 2006. 943 kB.

Regina, MJ. Biochemical changes associated with serotonergic hallucinogens. Ph. D. Thesis, State University of New York, Buffalo, NY, USA, 1 Jun 2005. 3431 kB.

McKenna, DJ; Saavedra, JM. Autoradiography of LSD and 2,5-dimethoxyphenylisopropylamine psychotomimetics demonstrates regional, specific cross-displacement in the rat brain. Eur. J. Pharmacol., 13 Oct 1987, 142 (2), 313–315. 263 kB. doi:10.1016/0014-2999(87)90121-X

Paulke, A; Kremer, C; Wunder, C; Achenbach, J; Djahanschiri, B; Elias, A; Schwed, JS; Hübner, H; Gmeiner, P; Proschak, E; Toennes, SW; Stark, H. Argyreia nervosa (Burm. f.): Receptor profiling of lysergic acid amide and other potential psychedelic LSD-like compounds by computational and binding assay approaches. J. Ethnopharmacol., 9 Jul 2013, 148 (2), 492–497. 555 kB. doi:10.1016/j.jep.2013.04.044

Watts, VJ; Mailman, RB; Lawler, CP; Neve, KA; Nichols, DE. LSD and structural analogs: Pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 1 Jan 1995, 118 (4), 401–409. 1367 kB. doi:10.1007/BF02245940

Shulgin, AT. LSD and pregnancy. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 28 Jan 2004.

Marona-Lewicka, D; Nichols, CD; Nichols, DE. An animal model of schizophrenia based on chronic LSD administration: Old idea, new results. Neuropharmacology, 1 Sep 2011, 61 (3), 503–512. 803 kB. doi:10.1016/j.neuropharm.2011.02.006

Wurst, M; Kysilka, R; Flieger, M. Psychoactive tryptamines from Basidiomycetes. Folia Microbiol., 1 Feb 2002, 47 (1), 3–27. 3077 kB. doi:10.1007/BF02818560

Marona-Lewicka, D; Kurrasch-Orbaugh, DM; Selken, JR; Cumbay, MG; Lisnicchia, JG; Nichols, DE. Re-evaluation of lisuride pharmacology: 5-hydroxytryptamine1A receptor-mediated behavioural effects overlap its other properties in rats. Psychopharmacology, 1 Oct 2002, 164 (1), 93–107. 293 kB. doi:10.1007/s00213-002-1141-z

Urban, JD; Clarke, WP; Zastrow, M; Nichols, DE; Kobilka, B; Weinstein, H; Javitch, JA; Roth, BL; Christopoulos, A; Sexton, PM; Miller, KJ; . Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther., 1 Jan 2007, 320 (1), 1–13. 506 kB. doi:10.1124/jpet.106.104463

Meyers-Riggs, B. Non-LSD ergoloids. countyourculture: rational exploration of the underground, 1 Dec 2011.

Halberstadt, AL; Geyer, MA. Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens. Neuropharmacology, 1 Sep 2011, 61 (3) 364–381. 817 kB. doi:10.1016/j.neuropharm.2011.01.017

Schindler, EAD; Dave, KD; Smolock, EM; Aloyo, VJ; Harvey, JA. Serotonergic and dopaminergic distinctions in the behavioral pharmacology of (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Pharmacol. Biochem. Behav., 1 Mar 2012, 101 (1), 69–76. 722 kB. doi:10.1016/j.pbb.2011.12.002

Ray, TS. Psychedelics and the human receptorome. PLOS ONE, 2 Feb 2010, 5 (2), e9019. 791 kB. doi:10.1371/journal.pone.0009019

Blaazer, AR; Smid, P; Kruse, CG. Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT2A receptors. ChemMedChem, 15 Sep 2008, 3 (9), 1299–1309. 461 kB. doi:10.1002/cmdc.200800133

Hoffman, AJ; Nichols, DE. Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. J. Med. Chem., 1 Jan 1985, 28 (9), 1252–1255. 583 kB. doi:10.1021/jm00147a022

Huang, X; Marona-Lewicka, D; Pfaff, RC; Nichols, DE. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives. Pharmacol. Biochem. Behav., 1 Jan 1994, 47 (3), 667–673. 650 kB. doi:10.1016/0091-3057(94)90172-4

Pfaff, RC; Huang, X; Marona-Lewicka, D; Oberlender, R; Nichols, DE. Lysergamides revisited. In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1994; pp 52–73. 181 kB.

Braden, MR. Towards a biophysical understanding of hallucinogen action. Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2007. 8442 kB.

Shulgin, AT. Morning glory seeds. Ask Dr. Shulgin Online, Center for Cognitive Liberty & Ethics, 17 Oct 2002.

Lieberman, JA; Mailman, RB; Duncan, G; Sikich, L; Chakos, M; Nichols, DE; Kraus, JE. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol. Psychiat., 1 Dec 1998, 44 (11), 1099–1117. 154 kB. doi:10.1016/S0006-3223(98)00187-5

Nichols, DE. Structural correlation between apomorphine and LSD: Involvement of dopamine as well as serotonin in the actions of hallucinogens. J. Theor. Biol., 1 Jun 1976, 59 (1), 167–177. 614 kB. doi:10.1016/S0022-5193(76)80030-6

Oberlender, R; Pfaff, RC; Johnson, MP; Huang, X; Nichols, DE. Stereoselective LSD-like activity in d-lysergic acid amides of R- and S-2-aminobutane. J. Med. Chem., 1 Jan 1992, 35 (2), 203–211. 1143 kB. doi:10.1021/jm00080a001

Shulgin, AT. Profiles of psychedelic drugs. 9. LSD. J. Psychedelic Drugs, 1 Jan 1980, 12 (2), 173–174. 1025 kB. doi:10.1080/02791072.1980.10471571

Anderson, GM; Braun, G; Braun, U; Nichols, DE; Shulgin, AT. Absolute configuration and psychotomimetic activity. In QuaSAR: Quantitative Structure Activity Relationships of Analgesics, Narcotic Antagonists, and Hallucinogens. NIDA Research Monograph 22; Barnett, G; Trsic, M; Willette, RE, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1978; pp 8–15. 457 kB.

Shulgin, AT. Chemistry and structure-activity relationships of the psychotomimetics. In Psychotomimetic Drugs; Efron, DH, Ed., Raven Press, New York, 1 Jan 1970; pp 21–41. 8647 kB.

Abramson, HA. Lysergic acid diethylamide (LSD-25) XXXI. Comparison by questionnaire of psychotomimetic activity of congeners on normal subjects and drug addicts. Br. J. Psychiatry, 1 Jul 1960, 106 (444), 1120–1123. 425 kB. doi:10.1192/bjp.106.444.1120

Vollenweider, FX; Kometer, M. The neurobiology of psychedelic drugs: implications for the treatment of mood disorders. Nat. Rev. Neurosci., 1 Sep 2010, 11 (9), 642–651. 588 kB. doi:10.1038/nrn2884

Braden, MR; Nichols, DE. Assessment of the roles of serines 5.43(239) and 5.46(242) for binding and potency of agonist ligands at the human serotonin 5-HT2A receptor. Mol. Pharmacol., 1 Jan 2007, 72 (5), 1200–1209. 487 kB. doi:10.1124/mol.107.039255

5301
Analogue 2: Substituting Acetyl for Methyl at R1

ALD-52
1-Acetyl-LSD
1-Acetyl-N,N-diethyllysergamide

IUPAC: (8β)-1-Acetyl-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide

Formula: C22H27N3O2 Molecular weight: 365.46868 g/mol InChI Key: FJOWXGYLIWJFCH-OXQOHEQNSA-N

InChI=1S/C22H27N3O2/c1-5-24(6-2)22(27)16-10-18-17-8-7-9-19-21(17)15(13-25(19)14(3)26)11-20(18)23(4)12-16/h7-10,13,16,20H,5-6,11-12H2,1-4H3/t16-,20-/m1/s1

PubChem CID: 201111; ChemSpider: 174121; Wikipedia: ALD-52

See also TiHKAL: #26 LSD        

Abramson, HA. Lysergic acid diethylamide (LSD-25) XXXI. Comparison by questionnaire of psychotomimetic activity of congeners on normal subjects and drug addicts. Br. J. Psychiatry, 1 Jul 1960, 106 (444), 1120–1123. 425 kB. doi:10.1192/bjp.106.444.1120

5303
Analogue 3: Substituting Hydroxymethyl for Methyl at R1

1-Hydroxymethyl-LSD
OML-632
N,N-Diethyl-1-hydroxymethyllysergamide

IUPAC: (8β)-N,N-Diethyl-1-(hydroxymethyl)-6-methyl-9,10-didehydroergoline-8-carboxamide

Formula: C21H27N3O2 Molecular weight: 353.45798 g/mol InChI Key: MCNBQMJSTKRHKK-DNVCBOLYSA-N

InChI=1S/C21H27N3O2/c1-4-23(5-2)21(26)15-9-17-16-7-6-8-18-20(16)14(12-24(18)13-25)10-19(17)22(3)11-15/h6-9,12,15,19,25H,4-5,10-11,13H2,1-3H3/t15-,19-/m1/s1

See also TiHKAL: #26 LSD        
5304
Analogue 4: Substituting Dimethylaminomethyl for Methyl at R1

1-Dimethylaminomethyl-LSD
N,N-Diethyl-1-dimethylaminomethyllysergamide

IUPAC: (8β)-1-[(Dimethylamino)methyl]-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide

Formula: C23H32N4O Molecular weight: 380.52638 g/mol InChI Key: NSFZERINUKJKQV-DYESRHJHSA-N

InChI=1S/C23H32N4O/c1-6-26(7-2)23(28)17-11-19-18-9-8-10-20-22(18)16(12-21(19)25(5)13-17)14-27(20)15-24(3)4/h8-11,14,17,21H,6-7,12-13,15H2,1-5H3/t17-,21-/m1/s1

See also TiHKAL: #26 LSD        
Two R2 analogues:
5307
Analogue 1: Adding Bromo at R2

MBL-61
2-Bromo-1-methyl-LSD
2-Bromo-N,N-diethyl-1-methyllysergamide

IUPAC: (8β)-2-Bromo-N,N-diethyl-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide

Formula: C21H26BrN3O Molecular weight: 416.35464 g/mol InChI Key: KLMFUBCMJSPRPY-FZKQIMNGSA-N

InChI=1S/C21H26BrN3O/c1-5-25(6-2)21(26)13-10-15-14-8-7-9-17-19(14)16(20(22)24(17)4)11-18(15)23(3)12-13/h7-10,13,18H,5-6,11-12H2,1-4H3/t13-,18-/m1/s1

PubChem CID: 170844; ChemSpider: 149365

See also TiHKAL: #26 LSD        
5308
Analogue 2: Adding Iodo at R2

2-Iodo-1-methyl-LSD
MIL
N,N-Diethyl-2-iodo-1-methyllysergamide

IUPAC: (8β)-N,N-Diethyl-2-iodo-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide

Formula: C21H26IN3O Molecular weight: 463.35511 g/mol InChI Key: TWQOQCUIXUGDKO-FZKQIMNGSA-N

InChI=1S/C21H26IN3O/c1-5-25(6-2)21(26)13-10-15-14-8-7-9-17-19(14)16(20(22)24(17)4)11-18(15)23(3)12-13/h7-10,13,18H,5-6,11-12H2,1-4H3/t13-,18-/m1/s1

PubChem CID: 126269; ChemSpider: 112233

See also TiHKAL: #26 LSD        
One skeleton analogue:
5342
Analogue 1: With Lysergic acid-cyclic-amine skeleton

MPD-75
1-Methyl-N-pyrrolidyllysergamide

IUPAC: [(8β)-6-Methyl-9,10-didehydroergolin-8-yl](pyrrolidin-1-yl)methanone

Formula: C21H25N3O Molecular weight: 335.4427 g/mol InChI Key: PWISINPCTJKXCA-DNVCBOLYSA-N

InChI=1S/C21H25N3O/c1-22-12-14-11-19-17(16-6-5-7-18(22)20(14)16)10-15(13-23(19)2)21(25)24-8-3-4-9-24/h5-7,10,12,15,19H,3-4,8-9,11,13H2,1-2H3/t15-,19-/m1/s1

PubChem CID: 201987; ChemSpider: 174911

See also TiHKAL: #26 LSD        
Six isomers:
5012
Isomer 1

ETH-LAD
N-Ethyl-nor-LSD
6-Norlysergic acid, 6,N,N-triethylamide
6-Norlysergamide, 6,N,N-triethyl
6,N,N-Triethyl-6-norlysergamide
N-(6)-Ethylnorlysergic acid, N,N-diethylamide
9,10-Didehydro-N,N,6-triethylergoline-8β-carboxamide

IUPAC: (8β)-N,N,6-Triethyl-9,10-didehydroergoline-8-carboxamide

Formula: C21H27N3O Molecular weight: 337.45858 g/mol InChI Key: MYNOUXJLOHVSMQ-DNVCBOLYSA-N

InChI=1S/C21H27N3O/c1-4-23(5-2)21(25)15-10-17-16-8-7-9-18-20(16)14(12-22-18)11-19(17)24(6-3)13-15/h7-10,12,15,19,22H,4-6,11,13H2,1-3H3/t15-,19-/m1/s1

PubChem CID: 44457783; ChemSpider: 21106300; Wikipedia: ETH-LAD

See also TiHKAL: #1 AL-LAD #26 LSD #51 PRO-LAD    

Hoffman, AJ; Nichols, DE. Synthesis and LSD-like discriminative stimulus properties in a series of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives. J. Med. Chem., 1 Jan 1985, 28 (9), 1252–1255. 583 kB. doi:10.1021/jm00147a022

Meyers-Riggs, B. Non-LSD ergoloids. countyourculture: rational exploration of the underground, 1 Dec 2011.

Watts, VJ; Mailman, RB; Lawler, CP; Neve, KA; Nichols, DE. LSD and structural analogs: Pharmacological evaluation at D1 dopamine receptors. Psychopharmacology, 1 Jan 1995, 118 (4), 401–409. 1367 kB. doi:10.1007/BF02245940

5317
Isomer 2

N-Pentyllysergamide

IUPAC: (8β)-6-Methyl-N-pentyl-9,10-didehydroergoline-8-carboxamide

Formula: C21H27N3O Molecular weight: 337.45858 g/mol InChI Key: ZWLCMQVCVMIVGG-DNVCBOLYSA-N

InChI=1S/C21H27N3O/c1-3-4-5-9-22-21(25)15-10-17-16-7-6-8-18-20(16)14(12-23-18)11-19(17)24(2)13-15/h6-8,10,12,15,19,23H,3-5,9,11,13H2,1-2H3,(H,22,25)/t15-,19-/m1/s1

PubChem CID: 15815935

See also TiHKAL: #26 LSD        
5318
Isomer 3

N-Pentan-2-yllysergamide

IUPAC: (8β)-6-Methyl-N-(pentan-2-yl)-9,10-didehydroergoline-8-carboxamide

Formula: C21H27N3O Molecular weight: 337.45858 g/mol InChI Key: JGLCNUHMSLNTLJ-NWLOPNIYSA-N

InChI=1S/C21H27N3O/c1-4-6-13(2)23-21(25)15-9-17-16-7-5-8-18-20(16)14(11-22-18)10-19(17)24(3)12-15/h5,7-9,11,13,15,19,22H,4,6,10,12H2,1-3H3,(H,23,25)/t13?,15-,19-/m1/s1

PubChem CID: 10427207; ChemSpider: 23240517

See also TiHKAL: #26 LSD        

Nichols, DE; Monte, A; Huang, X; Marona-Lewicka, D. Stereoselective pharmacological effects of lysergic acid amides possessing chirality in the amide substituent. Behav. Brain Sci., 15 Dec 1995, 73 (1–2), 117–119. 267 kB. doi:10.1016/0166-4328(96)00080-0

Monte, AP; Marona-Lewicka, D; Kanthasamy, A; Sanders-Bush, E; Nichols, DE. Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. J. Med. Chem., 1 Jan 1995, 38 (6), 958–966. 1156 kB. doi:10.1021/jm00006a015

Nichols, DE. LSD and its lysergamide cousins. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 80–87. 270 kB.

5319
Isomer 4

LSP
N-Pentan-3-yllysergamide

IUPAC: (8β)-6-Methyl-N-(pentan-3-yl)-9,10-didehydroergoline-8-carboxamide

Formula: C21H27N3O Molecular weight: 337.45858 g/mol InChI Key: ZQONRMXCBQXYCK-AUUYWEPGSA-N

InChI=1S/C21H27N3O/c1-4-15(5-2)23-21(25)14-9-17-16-7-6-8-18-20(16)13(11-22-18)10-19(17)24(3)12-14/h6-9,11,14-15,19,22H,4-5,10,12H2,1-3H3,(H,23,25)/t14-,19-/m1/s1

PubChem CID: 10019984; ChemSpider: 8195557

See also TiHKAL: #26 LSD        

Monte, AP; Marona-Lewicka, D; Kanthasamy, A; Sanders-Bush, E; Nichols, DE. Stereoselective LSD-like activity in a series of d-lysergic acid amides of (R)- and (S)-2-aminoalkanes. J. Med. Chem., 1 Jan 1995, 38 (6), 958–966. 1156 kB. doi:10.1021/jm00006a015

Nichols, DE. LSD and its lysergamide cousins. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 80–87. 270 kB.

Meyers-Riggs, B. Non-LSD ergoloids. countyourculture: rational exploration of the underground, 1 Dec 2011.

5330
Isomer 5

N-Ethyl-N-propyllysergamide

IUPAC: (8β)-N-Ethyl-6-methyl-N-propyl-9,10-didehydroergoline-8-carboxamide

Formula: C21H27N3O Molecular weight: 337.45858 g/mol InChI Key: LRVSYILBFXYJOP-DNVCBOLYSA-N

InChI=1S/C21H27N3O/c1-4-9-24(5-2)21(25)15-10-17-16-7-6-8-18-20(16)14(12-22-18)11-19(17)23(3)13-15/h6-8,10,12,15,19,22H,4-5,9,11,13H2,1-3H3/t15-,19-/m1/s1

See also TiHKAL: #26 LSD        

Bailey, K; Verner, D; Legault, D. Distinction of some dialkyl amides of lysergic and iso-lysergic acids from LCD. J. Assoc. Anal. Chem., 1973, 56 (1), 88–99. 513 kB.

5569
Isomer 6

EIPLA
N-Ethyl-N-isopropyllysergamide

IUPAC: (8β)-N-Ethyl-6-methyl-N-(propan-2-yl)-9,10-didehydroergoline-8-carboxamide

Formula: C21H27N3O Molecular weight: 337.45858 g/mol InChI Key: JLPRDEGOBAGMHN-DNVCBOLYSA-N

InChI=1S/C21H27N3O/c1-5-24(13(2)3)21(25)15-9-17-16-7-6-8-18-20(16)14(11-22-18)10-19(17)23(4)12-15/h6-9,11,13,15,19,22H,5,10,12H2,1-4H3/t15-,19-/m1/s1

Huang, X; Marona-Lewicka, D; Pfaff, RC; Nichols, DE. Drug discrimination and receptor binding studies of N-isopropyl lysergamide derivatives. Pharmacol. Biochem. Behav., 1 Jan 1994, 47 (3), 667–673. 650 kB. doi:10.1016/0091-3057(94)90172-4

Pfaff, RC; Huang, X; Marona-Lewicka, D; Oberlender, R; Nichols, DE. Lysergamides revisited. In Hallucinogens: An update. NIDA Research Monograph 146; Lin, GC; Glennon, RA, Eds., U.S. Department of Health and Human Services, National Institute of Health, U.S. Government Printing Office, Washington, DC, 1 Jan 1994; pp 52–73. 181 kB.

Nichols, DE. LSD and its lysergamide cousins. In Heffter Review; Nichols, DE, Ed., Heffter Research Institute, Santa Fe, NM, 2001; Vol. 2, pp 80–87. 270 kB.

Show all 15 analogues and isomers Show only the two N analogues Show only the four R1 analogues Show only the two R2 analogues Show only the one skeleton analogues
Page updated 31 October 2014 · This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License ·